We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
-24.24%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
–
AUM
$129M
AUM Growth
+$16.5M
Cap. Flow
+$48.3M
Cap. Flow %
37.36%
Top 10 Hldgs %
78.45%
Holding
25
New
6
Increased
10
Reduced
2
Closed
2

Top Buys

Rank Stock Value
1
ALDR
Alder Biopharmaceuticals
ALDR
+$24.3M
2
AERI
Aerie Pharmaceuticals
AERI
+$11.5M
3
ARDX icon
Ardelyx
ARDX
+$6.38M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$3.68M
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$3.27M

Top Sells

Rank Stock Value
1
XENT
Intersect ENT, Inc
XENT
+$570K
2
LRMR icon
Larimar Therapeutics
LRMR
+$321K

Sector Composition

Rank Sector Weight
1 Healthcare 84.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALDR
1
DELISTED
Alder Biopharmaceuticals
ALDR
$31.3M 24.23%
1,278,570
+1,048,675
+456% +$24.3M
WVE icon
2
Wave Life Sciences
WVE
$1.14B
$17.9M 13.81%
1,411,749
+1,060
+0.1% +$14.8K
AERI
3
DELISTED
Aerie Pharmaceuticals
AERI
$11.6M 9.01%
957,126
+724,369
+311% +$11.5M
GBT
4
DELISTED
Global Blood Therapeutics, Inc.
GBT
$7.88M 6.1%
497,000
+37,000
+8% +$657K
LRMR icon
5
Larimar Therapeutics
LRMR
$394M
$7.02M 5.43%
87,570
-4,072
-4% -$321K
EPZM
6
DELISTED
Epizyme, Inc
EPZM
$5.78M 4.47%
476,777
+15,126
+3% +$153K
RGLS
7
DELISTED
Regulus Therapeutics
RGLS
$5.47M 4.23%
6,576
+584
+10% +$465K
ARDX icon
8
Ardelyx
ARDX
$1.25B
$5.04M 3.9%
+648,340
New +$6.38M
AIMT
9
DELISTED
Aimmune Therapeutics
AIMT
$4.81M 3.72%
355,020
– –
AVXS
10
DELISTED
AveXis, Inc. Common Stock
AVXS
$4.58M 3.55%
+168,195
New +$3.68M
NDRM
11
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$4.13M 3.19%
292,371
+30,426
+12% +$411K
LPCN icon
12
Lipocine
LPCN
$17.6M
$4.03M 3.12%
23,359
+3,947
+20% +$674K
AKTX
13
Akari Therapeutics
AKTX
$14.7M
$3.69M 2.86%
330
– –
SGMO
14
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$3.3M 2.55%
+544,816
New +$3.27M
XENT
15
DELISTED
Intersect ENT, Inc
XENT
$3.2M 2.48%
168,550
-31,450
-16% -$570K
XLRN
16
DELISTED
Acceleron Pharma
XLRN
$2.49M 1.93%
94,403
+44,356
+89% +$1.29M
BLCM
17
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.93M 1.49%
+20,599
New +$2.24M
OREX
18
DELISTED
Orexigen Therapeutics, Inc.
OREX
$1.7M 1.32%
302,735
+2,735
+0.9% +$35.5K
RGNX icon
19
Regenxbio
RGNX
$613M
$1.08M 0.84%
100,000
– –
DMTX
20
DELISTED
Dimension Therapeutics, Inc
DMTX
$770K 0.6%
98,297
– –
BDSI
21
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$670K 0.52%
+207,498
New +$767K
EDIT icon
22
Editas Medicine
EDIT
$399M
$501K 0.39%
+14,500
New +$381K
IMGN
23
DELISTED
Immunogen Inc
IMGN
$365K 0.28%
42,815
– –
XLRN
24
PUT
DELISTED
Acceleron Pharma
XLRN
– –
-100,000
Closed -$4.88M
DYAX
25
CALL
DELISTED
DYAX CORPORATION
DYAX
– –
-55,900
Closed -$2.1M

Similar funds

PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return
HLC
Hunt Lane Capital New York $39.6M AUM 58.74% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Foresite Capital Management III's Q1 2016 Portfolio in Review

As of Q1 2016, Foresite Capital Management III held 25 positions worth $129M, up 15% from $113M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Foresite Capital Management III deployed $48.3M of net new capital in Q1 2016, opening 6 new positions and adding to 10 existing holdings. Its largest new stake was Ardelyx: 648,340 shares worth $5.04M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 79% a quarter earlier.

On the sell side, the largest reduction was Intersect ENT, Inc, an estimated $570K trimmed.

  • Foresite Capital Management III's largest Q1 2016 buy was Ardelyx: 648,340 shares worth $5.04M.
  • Foresite Capital Management III added most to Alder Biopharmaceuticals in Q1 2016, an estimated $24.3M increase.
  • Foresite Capital Management III's biggest Q1 2016 reduction was Intersect ENT, Inc, cutting an estimated $570K.
  • Foresite Capital Management III's ten largest holdings make up 78% of its $129M portfolio in Q1 2016.
  • Foresite Capital Management III opened 6 new positions and closed 2 in Q1 2016.
  • Foresite Capital Management III's portfolio value rose 15% quarter-over-quarter to $129M.

Based on Foresite Capital Management III's 13F filing for Q1 2016, filed 6 May 2016.